944. Perinatal Case Fatality Rate Related to Congenital Zika Syndrome in Brazil: a Cross-Sectional Study

Igor Thiago Queiroz, MD, PhD; Jessica Thais Da Silva Maia, MS; Gleyson Rosa, RN, MD; Tatyana Vidal Mendes, RN, S; Jayne Alves Vidal, RN, S; Maria Goretti Lins, MD, Marcelo Rodrigues Zacarkin, MD, MD; Davi Aronoff, MD, FIDSA; A. Desirine, MA; Nicolas M. Wilson, M. FIDSA; Ricardo Potuguez, Natal, Brazil; Universidade Potiguar; Natal – RN, Brazil; 2Harvard Medical School, Boston, Massachusetts; Secretaria Municipal de Saúde, Caiçaras-PB, caiçaras-PB, Brazil; 3SESAP - Rio Grande do Norte, Natal, Brazil; 4Hospital Infantil Variaguatey, Natal, Brazil; 5Vanderbilt University School of Medicine, Division of Infectious Diseases, Nashville, Tennessee; 6Pediatric Infectious Diseases, Stanford University, Stanford, California; 7Extension Center, University of California, Davis, Davis, California

Session: 121. Emerging Paradigms: Pediatric Viral Infections
Friday, October 6, 2017: 8:30 AM

Background. Many studies have demonstrated a causal link between Zika virus (ZIKV) infection, microcephaly (MCP), and other congenital abnormalities (CA). This study aimed to determine perinatal case fatality rate in cases of Congenital Zika Syndrome (CZS) in the Rio Grande do Norte State (RN), a Brazilian Northeast State highly impacted by the Zika virus outbreak.

Methods. A cross-sectional study was conducted using data obtained through the State Health Department (SHE) for cases of MCP and CA in Rio Grande do Norte from April 1, 2015 to February 5, 2016. Definition of perinatal period: commencement at 22 completed weeks (154 days) of gestation and ends seven completed days after birth.

Results. During the study period, there were 486 cases of MCP and other CA notified. Of 61% of newborns were confirmed and 108 remain under investigation. The remaining 236 cases have been ruled out by presenting normal examinations or due to presenting microcephaly by noninfectious causes. Of the total confirmed cases, 26.7% (36/142) died after birth or during pregnancy. 15.7% (60/38) of confirmed deaths had ZIKV exposure during pregnancy. 63.6% (30/48) had a positive TORCH blood test. The six cases related to ZIKV were confirmed by RT-PCR and/or IgM/IgG antibodies against ZIKV. The remaining cases of deaths remain either under investigation or have been ruled out.

Conclusion. This study highlights a high rate of perinatal lethality (15.7%) in cases of CZS. Despite the growing number of CZS cases, the real incidence and prevalence might be higher due to the underreporting and lack of resources for confirmatory diagnostic tests (laboratory and imaging). Due to the high rate of lethality and the ongoing uncontrolled ZIKV outbreak, this study predicts an increase in the infant mortality rate in Brazil and highlights the need for developing public health programs to control the ZIKV outbreak.

Disclosures. All authors: No reported disclosures.

946. Maternal Immunization with a Single-Cycle Herpes Simplex Virus (HSV) Candidate Vaccine, ΔgD-2, Protects Neonatal Mice from Lethal Viral Challenge

Carol Kuo, MD; Clare Burn, MS; William R Jacobs Jr, PhD; Betsy C. Herold, MD, FIDSA, FPIDS; 2Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York; 3Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; 4Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, New York

Session: 121. Emerging Paradigms: Pediatric Viral Infections
Friday, October 6, 2017: 8:30 AM

Background. Perinatal HSV is associated with ~60% mortality if untreated and with substantial morbidity even with appropriate therapy. We recently engineered a vaccine that deletes in glycoprotein D (ΔgD-2) that induces high-titer antibodies (Abs) that are non-neutralizing but activate the Fe receptor (Fcr) to elicit antibody-dependent cellular cytotoxicity (ADCC). Immunization with ΔgD-2 completely protects adult mice from HSV-1 and HSV-2 disease following vaginal, skin, intracutaneous, or intranasal challenge and prevents the establishment of latency (ELife, 2014, JCI Insight, 2016). Thus we hypothesize that maternal immunization with ΔgD-2 and/or passive transfer of immune serum will protect neonates from HSV.

Methods. Four- to six-week-old C57Bl6 female mice were primed and boosted at 3-week intervals with ΔgD-2 or ΔgD-2 plus ΔgD-2 measured by HSV-1 or HSV-2 in neural tissue (V cells). Two weeks post-boost, mice were mated and pups were challenged with a lethal dose of HSV-1 (B3RX1.1) at day 7 of birth. To differentiate the contribution of transplacental vs. colostrum Abs, mothers were switched at birth. Alternatively, 7-day-old mice born to nonimmunized mothers received a single dose of immune serum (400 μg total Ab) intraperitoneally at time of intranasal challenge.

Results. Thirty-eight of 47 (81%) of the pups born to and nursed by ΔgD-2-immunized mothers survived, exhibited little if no signs of disease and were protected against intranasal challenge but not against subcutaneous challenge measured by HSV-1 or HSV-2 in neural tissue (V cells). In contrast, 12/14 (86%) of pups born to control vaccinated and nursed mice developed neurological signs of disease and died (P < 0.0001, Fisher’s exact test). Survival was associated with increased ADCc Abs in the serum of neonatal mice. In contrast, passive transfer of immune serum, which consistently protects adult mice from infection, did not protect neonates. If newborns born to immunized mice sucked with control milk, protection was partially abrogated (11/19, 58%) survival, suggesting that both systemic and mucosal Abs are required for complete protection.

Conclusion. Maternal vaccination with ΔgD-2 provides significant protective against intranasal neonatal challenge but may require exposure to systemic and mucosal Abs.

Disclosures. W. R. Jacobs Jr., xxv: Scientific Advisor, Research support; B. C. Herold, X.vac: Grant Investigator, Research grant and Research support

947. Blood Viral Load (VL) Not Clinically Meaningful in Symptomatic Congenital Cytomegalovirus (cCMV) Infection

Constance Marsico, MD, MPH; Natalia E Mariscos, MD, PhD; Huichien Kuo, MS, PhD; Pablo Sanchez, MD, FIDSA, FPIDS; Amna Ahmed, MD; Ravit Arav-Boger, MD, Marian Michaels, MD, MPH, Negash Ashouri, MD; Janet Englund, MD, FIDSA; Benjamin Estrada, MD, FPIDS; Richard Jacobs, MD, FIDSA, FPIDS; Jose R. Romero, MD; Sunil Seshadri, MD, FIDSA; Huichien Kuo, MS, PhD; Scott H. James, MD, MPH; Penny Jester, RN; Richard Whitley, MD, FIDSA, FPIDS; David W. Kimberlin, MD, FIDSA, FPIDS and Collaborative Antiviral Study Group (CAG); 1University of Bologna, Bologna, Italy; 2University of Alabama at Birmingham, Birmingham, Alabama; 3Pediatrics, Division of Pediatric Infectious Diseases and Neonatology, Nationwide Children’s Hospital – Ohio State University College of Medicine, Columbus, Ohio; 4Pediatrics, Carolinas Medical Center, Charlotte, North Carolina; 5Johns Hopkins, Baltimore, Maryland; 6Pediatrics, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania; 7Infectious Diseases, CHOC Children’s Hospital, Orange, California; 8University of Washington/Seattle Children’s Hospital, Seattle, Washington; 9University of South Alabama, Mobile, Alabama; 10University of Arkansas for Medical Sciences, Little Rock, Arkansas; 11University of Arkansas for Medical Sciences, Little Rock, Arkansas; 12Steven and Alexandra Cohen Children’s Medical Center, New Hyde Park, New York; 13Cook Children’s Medical Center, Fort Worth, Texas; 14Pediatrics, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama; 15Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama

Session: 121. Emerging Paradigms: Pediatric Viral Infections
Friday, October 6, 2017: 8:30 AM

Background. Sensory neuronal hearing loss (SNHL) and neurodevelopmental (ND) outcomes are unfavorably impacted by antiviral therapy in infants with symptomatic congenital CMV disease. We correlated blood VL before and during therapy with clinical findings at presentation and follow-up in this population.

Methods. Post-hoc analysis of two clinical trials conducted by the CASG from 2002 to 2013 evaluating valganciclovir therapy. 120 subjects (73 treated × 6 weeks, 47

Conclusion. FeMRI and fUS provide complimentary information in the assessment of fetal brain changes in ZIKV. In cases of abnormal brain structure, fMRI reveals more extensive areas of brain damage than is seen by US. Further studies are needed to determine whether cystic changes on postnatal head US are related to ZIKV infection, or are incidental findings.

Disclosures. All authors: No reported disclosures.
treated × 6 months) were included. Whole blood VL was determined by real-time PCR at a central laboratory before therapy (baseline, BL) and periodically for 6 months.

**Results.** In subjects treated for 6 months, increases in BL VL correlated with decreased probability of better hearing outcomes at 12 months (Figure 1), but clinically meaningful VL thresholds that predict SNHL were not identified (Table 1). Subjects treated for 6 weeks had no correlation between BL VL and SNHL. No correlation was found between BL VL and Bayley ND testing at 12 and 24 months for subjects receiving either treatment duration. Subjects treated for 6 months who achieved and sustained VL suppression (<2.5 log) between treatment day 1 and month 4 had better hearing outcomes at 6, 12, and 24 months (89% vs. 56%, P = 0.01; 100% vs. 63%, P = 0.0007; 94% vs. 68%, P = 0.04), but 56–68% of subjects not achieving suppression still had improved hearing. Higher BL VL correlated with BL CNS involvement, thrombocytopenia, and transaminase elevation for subjects receiving either treatment duration, but with substantial overlap in quantity of virus detected (Figure 2). Subjects with ≥3 symptoms of congenital CMV at presentation had higher BL VL than subjects with <3 symptoms (3.75 log, range 1.00–5.65, vs. 3.38 log, range 1.00–5.36; P = 0.005).

**Conclusion.** Blood VL at BL and during therapy has little clinically meaningful predictive value for long-term outcomes in symptomatic congenital CMV.

**Table 1**

| Hearing outcome | Improved/protected (no.) | Others (no.) | P-value | Negative predictive value (CI) | Positive predictive value (CI) |
|-----------------|--------------------------|-------------|---------|--------------------------------|-------------------------------|
| BL VL (log genome equivalent/ml) |                       |             |         |                                |                               |
| 12 months       | 43                        | 20          | 0.10    | 93 (79–100)                    | 32 (20–43)                    |
| >3              | 13                       | 1           |         |                                |                               |
| ≤3              | 8                        | 9           | 0.01    | 80 (70–90)                     | 53 (29–77)                    |
| >4.5            | 4                        | 12          |         |                                |                               |
| ≤4.5            | 42                       | 14          | 0.72    | 83 (62–100)                    | 25 (14–36)                    |
| 24 months       | 42                       | 14          |         |                                |                               |
| >3              | 10                       | 2           |         |                                |                               |
| ≤3              | 5                        | 5           | 0.32    | 79 (68–90)                     | 33 (9–67)                     |
| >4.5            | 42                       | 11          |         |                                |                               |

**Figure 1**

**Figure 2**

**Disclosures.** J. Englund, Gilead: Consultant and Investigator, Research support; Chimerix: Investigator, Research support; Alios: Investigator, Research support; Novavax: Investigator, Research support; MedImmune: Investigator, Research support; GlaxoSmithKline: Investigator, Research support

948. Incidence of UL97 Resistance Mutations in Infants with Congenital Cytomegalovirus Disease Receiving 6 Months of Oral Valganciclovir Therapy  
Scott H. James, MD1; RA’Shun L. Conner, MS, MBA2; David W. Kimberlin, MD, FIDSA3; FPIDS4; Richard Whitley, MD, FIDSA5; Mark N. Prichard, PhD6; Pediatrics, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama; 1University of Alabama at Birmingham, Birmingham, Alabama; 2Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama

**Session:** 121. Emerging Paradigms: Pediatric Viral Infections  
Friday, October 6, 2017: 8:30 AM

**Background.** A recently completed Phase 3 randomized, controlled, double-blind, multicenter study of infants with symptomatic congenital cytomegalovirus (CMV) disease receiving 6 months of oral valganciclovir (VGCV) therapy represents the largest population in which to evaluate treatment-emergent antiviral resistance. The most common mechanism of CMV antiviral resistance occurs through mutations in the CMV UL97 gene that confer resistance to ganciclovir (GCV). Genotypic resistance analyses were performed on infants receiving 6 months of VGCV to assess the incidence of antiviral resistance due to UL97 sequence variants.

**Methods.** Resistance analyses were performed by functional enzyme inhibition assay on the UL97 gene at multiple time points. Following CMV DNA extraction from frozen whole blood specimens, the UL97 gene was amplified with a double nested polymerase chain reaction method and sequenced to identify polymorphisms and mutations that might confer GCV resistance.

**Results.** Forty-six infants with symptomatic CMV disease who received a 6-month course of VGCV underwent resistance analysis to identify UL97 sequence variants. In addition to a range of natural polymorphisms known to have no effect on antiviral susceptibility, 2 subjects developed UL97 mutations known to confer resistance to GCV (A594V and G598S detected in one subject; E596G detected in another), yielding an incidence of 4%. Each of these resistance mutations occurred in specimens collected after at least 4 months of antiviral therapy. As evaluated in the original Phase 3 trial, neither of these infants showed an improvement in hearing outcomes.

**Conclusion.** The development of treatment-emergent UL97 resistance mutations was determined in a controlled study population of infants with congenital CMV disease receiving 6 months of VGCV. This targeted resistance analysis demonstrated an incidence approaching the total incidence of antiviral resistance for CMV disease in some immunocompromised populations, such as solid-organ transplant recipients. Further studies within this study population are warranted to elucidate the risk of emerging antiviral resistance and to assess clinical impact as well as the potential need for combination antiviral therapy.

**Disclosures.** All authors: No reported disclosures.

949. Programmatic Congenital CMV Universal Screening Program  
Maria Carrillo-Magpantay, MD1; Benjamin Robie, BS2; Ryan Tomlinson, BS3; Jacqueline Blanche, CNA4; Laura Bradford, RN5; Young In Kim-Hoehm, PhD6; Lisa Harrison, MLT7; Stephen Pace, BS1; Joe Davis, BS1; Chirag Patel, Montana8; Anami Patel, PhD9; Sandra R. Arnold, MD, MSc10; John P. Devincenzo, MD11; Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee; 1Le Bonheur Children’s Hospital, Memphis, Tennessee; 2Children’s Foundation Research Institute, Le Bonheur Children’s Hospital, Memphis, Tennessee; 3Division of Pediatrics, University of Tennessee School of Medicine, Memphis, Tennessee; 4Pediatrics, Le Bonheur Children’s Hospital, Memphis, Tennessee; 5Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee; 6University of Tennessee Molecular Diagnostics Laboratory, Le Bonheur Children’s Hospital, Memphis, Tennessee; 7Pediatrics, University of Tennessee Health Sciences Center, Memphis, Tennessee; 8Molecular Diagnostics Laboratory, Le Bonheur Children’s Hospital, Memphis, Tennessee; 9Pediatrics, University of Tennessee Health Sciences Center, Memphis, Tennessee; 10Department of Microbiology, Immunology, and Molecular Biology, University of Tennessee School of Medicine, Memphis, Tennessee

**Session:** 121. Emerging Paradigms: Pediatric Viral Infections  
Friday, October 6, 2017: 8:30 AM

**Background.** CMV is the most common congenital infection (cCMV). Traditional identification strategies including hearing screen and physical exam are insensitive and miss affected infants. To improve identification of infected newborns, we established a universal, institutional cCMV newborn screening program.

**Methods.** All newborns born or transferred to nurseries in a hospital system in Memphis, Tennessee between March 2016 and April 2017 who screened for cCMV, infant saliva was collected on a Copan swab prior to discharge and within 2 weeks of birth. Specimens were centrally processed using a real-time CMV PCR assay (Simplexa™ CMV) (DiSorin, Cypress CA) amplifying the UL83 gene, and the JM Integrated Cycler. Parents received educational materials on cCMV testing and natural history prior to specimen collection. All patients with a positive screen had a full evaluation including physical exam, eye exam, hearing testing, CBC, chemistries and head ultrasound (HUS).

**Results.** There were 35/6,114 (0.6%) positive screens. Of 35, 16 (45.7%) were male and 19 (54.3%) were female. Thirty of 35 saliva specimens were collected on day 0 or 1 of life. All patients were evaluated by an infectious disease specialist at a median of 15 days of age. Confirmatory urine PCR was positive in 25/33 (76%) tested. Overall, 11/25 (44%) with confirmed congenital CMV were symptomatic. Thirteen infants included 28% with microcephaly and 14% with low birth weight. Six (24%) failed newborn hearing screening of one or both ears. Other abnormalities included thrombocytopenia (5%), elevated ALT (10%), elevated direct bilirubin (5%), and abnormal HUS (11/25, 44%), of which 7/11 had leukocytosis vasculopathy and 2/11 had radiographic calcifications. None had any eye examination and none had retinopathy. Eleven infants were offered therapy and five were treated. Ten of 25 congenitally infected infants had audiology follow-up by 6 months with four abnormal. All infants were referred for early intervention.